0.9784
Hoth Therapeutics Inc stock is traded at $0.9784, with a volume of 6.03M.
It is up +0.38% in the last 24 hours and up +6.84% over the past month.
See More
Previous Close:
$0.9747
Open:
$1
24h Volume:
6.03M
Relative Volume:
0.72
Market Cap:
$12.82M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-0.7412
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
-4.08%
1M Performance:
+6.84%
6M Performance:
+18.16%
1Y Performance:
-28.58%
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HOTH
Hoth Therapeutics Inc
|
0.9784 | 12.82M | 0 | -7.51M | -8.02M | -1.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Hoth Flat on Hookup with Washington Univ. - Baystreet.ca
Hoth Therapeutics reports Alzheimer’s drug candidate success - Investing.com India
Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development - MarketScreener
Breakthrough: New Alzheimer's Drug Cuts Key Brain Marker by 15%University Study Reveals - Stock Titan
Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours - PR Newswire
Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World
Hoth Therapeutics receives USPTO filing receipt for HT-001 patent application - TipRanks
New Patent Filing Strengthens Hoth's Cancer Treatment IP PortfolioKey Details - Stock Titan
Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Hoth Therapeutics Inc. (HOTH) reports earnings - Quartz
Hoth Therapeutics, Inc. SEC 10-K Report - TradingView
Hoth Therapeutics enhances patent claims, begins toxicity study By Investing.com - Investing.com South Africa
Hoth Therapeutics enhances patent claims, begins toxicity study - Investing.com
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation - Marketscreener.com
Major Progress: Hoth's Cancer-Fighting Drug Secures Patent Protection and Launches Critical Safety Study - Stock Titan
Hoth Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Hoth Therapeutics (HOTH) Projected to Post Earnings on Thursday - Defense World
Balance Sheet Breakdown: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Hoth Therapeutics announces ‘positive’ results from study of HT-KIT - Yahoo Finance
Hoth reports progress in GIST treatment with HT-KIT By Investing.com - Investing.com Australia
Hoth reports progress in GIST treatment with HT-KIT - Investing.com India
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment - PR Newswire
Revolutionary 24-Hour Cancer Treatment Success: Hoth's HT-KIT Destroys GIST Tumors in Breakthrough Study - Stock Titan
Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Decreases By 24.8% - Defense World
Hoth Therapeutics to submit HT-001 expanded access application By Investing.com - Investing.com Australia
Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need - Marketscreener.com
Hoth Dips on Drug Application - Baystreet.ca
Hoth Therapeutics to submit Expanded Access application for HT-001 - TipRanks
Hoth Therapeutics to submit HT-001 expanded access application - Investing.com India
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need - PR Newswire
Hoth Therapeutics reports HT-001 cream success in skin toxicity By Investing.com - Investing.com South Africa
Hoth Therapeutics reports HT-001 cream success in skin toxicity - Investing.com India
Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate - TipRanks
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting - PR Newswire
Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Hoth Therapeutics Announces Positive Findings On GDNF's Potential As A Game-Changer In Obesity Treatment And Reduced Fatty Liver Disease - MarketScreener
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease - PR Newswire
GDNF shows promise in obesity treatment, Hoth research finds - Investing.com
Financial Contrast: Emmaus Life Sciences (OTCMKTS:EMMA) and Hoth Therapeutics (NASDAQ:HOTH) - Defense World
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN
Hoth Therapeutics (NASDAQ:HOTH) Given Buy Rating at D. Boral Capital - Defense World
Hoth Therapeutics to Present at the LD Micro Main Event (XII) - ACCESS Newswire
What to expect from HOTH’s earnings report this quarter? - US Post News
Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic - Contract Pharma
HOTH's Cancer Breakthrough: Strategic Alliance Accelerates Novel HT-KIT Therapeutic Research - StockTitan
Hoth Therapeutics expands at-the-market offering by $5 million - Investing.com Australia
Research Analysts Set Expectations for HOTH FY2024 Earnings - Defense World
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at HC Wainwright - Defense World
Hoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsNew York, NY – January 24, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced today that it has successfully regained compliance with the minimum bid price requirement s - Defense World
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):